摘要
目的 :评价紫杉醇联合顺铂或卡铂 (TP方案 )治疗晚期卵巢上皮癌的疗效。方法 :16例Ⅲ、Ⅳ期卵巢上皮癌患者 ,给予TP方案化疗 :紫杉醇剂量为 135mg/m2 ,溶于 5 %GS 5 0 0ml,静滴 10小时 ,第 1天 ;顺铂 (DDP)70～ 80mg/m2 ,第 2天 (或卡铂按AUC =5计算所得的剂量 ) ,前 3～ 4个疗程采用腹腔给药 ,其余均静脉给药。 2 4例对照组患者采用环磷酰胺 (CTX)加铂类药为主的“CP”方案 (其中包括“CAP”或“CVP”方案 ,A为多柔比星 ,V为长春新碱 )。结果 :TP方案化疗组 16例 ,CR为 5例 ,PR为 7例 ,总有效率为 75 % ;CP为主方案对照组 2 4例 ,CR 3例 ,PR 7例 ,总有效率为 4 1 7% ,两组间差异有显著性 (P <0 0 5 )。TP组中位生存期为 35个月 ,CP组中位生存期为 2 2 5个月 ,TP方案中位生存期显著高于CP方案对照组。结论 :TP方案是治疗晚期卵巢上皮癌较理想的方案。
Purpose:To evaluate the therapeutic effect of paclitaxel and platinum containing chemotherapy (cisplatin or carboplatin) in women with epithelial ovarian cancer.Methods:We assigned 16 cases with advanced epithelial ovarian cancer after initial surgery to receive paclitaxel and cisplatin or carboplatin. Pcalitaxel (135 mg/m 2,over a period of 10 hours ) was administered iv once every 3 to 4 weeks, 24 control cases were treated with 'CAP' or 'CVP' regimen. Results:The overall median survival was significantly longer in the paclitaxel platinum group than in the cisplatin cyclophosphamide group (median, 35 vs. 22.5 months, P <0.025). Among 16 women with measurable disease, 75 percent in the TP group responsed to therapy, as compared with 41.7 percent in the CP group ( P <0.05). Conclusions:Paclitazel and platinum agent are effective in the treatment of advanced epithelial ovarian cancer.
出处
《中国癌症杂志》
CAS
CSCD
2002年第3期249-250,288,共3页
China Oncology
